Patrys
Manufacturing · Australia · 1-10 Employees
View Company Info for Free
Overview
Headquarters
100 Albert Rd L 4, South Melbourne, Vict...Phone Number
(973) 714-6611Website
www.patrys.comRevenue
<$5 MillionStock Symbol
PABIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Patrys
Patrys Limited is a publicly-listed company dedicated to developing innovative antibody technologies aimed at treating hard-to-treat cancers and addressing acute delirium. The company is advancing a proprietary IV formulation of quetiapine for delirium, targeting patients in postoperative, intensive care, and palliative care settings. Additionally, Patrys is in the early stages of developing a versatile antibody platform, known as deoxymabs, which focuses on NETosis related to cancer and various inflammatory diseases. Their primary clients include patients suffering from these conditions and stakeholders interested in therapeutic advancements.Explore more
Patrys Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Patrys your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Patrys, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Patrys is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Patrys has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Patrys launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Patrys recently announced quarterly report
Funding: Get notified immidiatlly once Patrys has new funding data
Congratulate Masked Content for being promoted to Masked Content at Patrys
Click to see if Patrys had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Patrys
Compare insights from companies similar to Patrys, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Patrys is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Patrys is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Patrys.
Patrys Tech Stack
A closer look at the technologies used by Patrys
Patrys News & Media
Patrys Appoints Global Biotechnology Leader as Chairman - In Preparation for First Clinical Trial for Groundbreaking Cancer Therapy
MELBOURNE, Australia--(BUSINESS WIRE)--Patrys Limited (ASX: PAB, “Patrys” or the “Company”), a therapeutic antibody development company, has announced the appointment of Dr. Charmaine Gittleson as the Chairman of the Board of Directors – a highly respected and experienced global biotechnology leader. Dr. Gittleson is the former Chief Medical Officer of CSL Limited with more than 20 years of experience in pharmaceutical development in the USA and Australia. Dr. Gittleson’s expertise spans many aInvesting in Patrys (ASX:PAB) five years ago would have delivered you a 448% gain
Patrys Limited ( ASX:PAB ) shareholders might be concerned after seeing the share price drop 14% in the last quarter...Patrys Limited Announces Publication of PAT-DX1 Preclinical Data in JCI - Insight
MELBOURNE--(BUSINESS WIRE)---- $PAB #antibody--Patrys Limited (ASX:PAB), a therapeutic antibody development company, has announced the publication of preclinical data for its therapeutic antibody candidate PAT-DX1 in The Journal of Clinical Investigation—Insight. Patrys is developing PAT-DX1 for use in DDR-deficient cancers, including a range of primary brain cancers and metastases. PAT-DX1 is a cell-penetrating autoantibody that localizes into live cell nuclei, inhibits DNA repair, and is synthIf You Had Bought Patrys (ASX:PAB) Stock Three Years Ago, You Could Pocket A 117% Gain Today
It hasn't been the best quarter for Patrys Limited (ASX:PAB) shareholders, since the share price has fallen 28% in...
Read more news
Top Manufacturing Companies
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Patrys
Sign Up For FreeTo access detailed company insights
Patrys Limited is a publicly-listed company dedicated to developing innovative antibody technologies aimed at treating hard-to-treat cancers and addressing acute delirium. The company is advancing a proprietary IV formulation of quetiapine for delirium, targeting patients in postoperative, intensive care, and palliative care settings. Additionally,... Read More
